Bibliographic Details
| Title: |
Early Data Show Ongoing Benefit of Bria-IMT in Small Breast Cancer Population |
| Authors: |
By:Nicholas Wrigley |
| Source: |
CancerNetwork (USA), March 20, 2023 News, 3pp |
| Abstract: |
Targeted immunotherapy agent Bria-IMT (SV-BR-1-GM) continued to yield clinical survival benefit in combination with retifanlimab (MGA012) in 11 patients with advanced, metastatic breast cancer who were enrolled in a phase 1/2 trial (NCT03328026) in 2021 or 2022, according to data published in a press release from BriaCell Therapeutics. Investigators reported a median progression-free survival (PFS) of 3.5 months, with 1 patient who continued to be progression free... |
| Database: |
NewsBank |
